ES2182120T3 - Heteroariloxietilaminas como ligandos del receptor 5-ht1a. - Google Patents

Heteroariloxietilaminas como ligandos del receptor 5-ht1a.

Info

Publication number
ES2182120T3
ES2182120T3 ES97943000T ES97943000T ES2182120T3 ES 2182120 T3 ES2182120 T3 ES 2182120T3 ES 97943000 T ES97943000 T ES 97943000T ES 97943000 T ES97943000 T ES 97943000T ES 2182120 T3 ES2182120 T3 ES 2182120T3
Authority
ES
Spain
Prior art keywords
heteroariloxietilaminas
receiver
ligandos
ht1a
antiemetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97943000T
Other languages
English (en)
Inventor
Denis Bigg
Marie-Odile Galcera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Application granted granted Critical
Publication of ES2182120T3 publication Critical patent/ES2182120T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS HETEROARILOXIETILAMINAS QUE TIENEN UNA GRAN AFINIDAD PARA EL RECEPTOR 5 - HT SUB,1A , A PROCEDIMIENTOS DE PREPARACION, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SU UTILIZACION COMO MEDICAMENTOS Y PARTICULARMENTE COMO INHIBIDORES DE SECRECION DE ACIDO GASTRICO O COMO ANTIEMETICOS.
ES97943000T 1996-09-27 1997-09-26 Heteroariloxietilaminas como ligandos del receptor 5-ht1a. Expired - Lifetime ES2182120T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9611798A FR2753968B1 (fr) 1996-09-27 1996-09-27 Nouvelles heteroaryloxyethylamines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
ES2182120T3 true ES2182120T3 (es) 2003-03-01

Family

ID=9496126

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97943000T Expired - Lifetime ES2182120T3 (es) 1996-09-27 1997-09-26 Heteroariloxietilaminas como ligandos del receptor 5-ht1a.

Country Status (21)

Country Link
US (1) US6063784A (es)
EP (1) EP0929525B1 (es)
JP (1) JP2001503393A (es)
AR (1) AR008486A1 (es)
AT (1) ATE223380T1 (es)
AU (1) AU731459B2 (es)
BR (1) BR9711560A (es)
CA (1) CA2267247C (es)
DE (1) DE69715223T2 (es)
DK (1) DK0929525T3 (es)
ES (1) ES2182120T3 (es)
FR (1) FR2753968B1 (es)
HU (1) HUP0001189A3 (es)
IL (1) IL128917A (es)
MY (1) MY118992A (es)
NO (1) NO311935B1 (es)
NZ (1) NZ334623A (es)
PL (1) PL190221B1 (es)
RU (1) RU2176639C2 (es)
TW (1) TW425390B (es)
WO (1) WO1998013349A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4507398B2 (ja) * 1999-12-06 2010-07-21 宇部興産株式会社 ３−ハロメチルオキセタン化合物の合成方法
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
RU2234315C1 (ru) * 2003-06-30 2004-08-20 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон, метацин и бензамид

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
US5240800A (en) * 1991-07-29 1993-08-31 Eastman Kodak Company Near-infrared radiation sensitive photoelectrographic master and imaging method
EP0643045B1 (de) * 1993-09-10 2000-03-08 Novartis AG Chinolin-Verbindungen als Leukotriene Antagonisten
GB9507288D0 (en) * 1995-04-07 1995-05-31 Sod Conseils Rech Applic Phenoxyethylamine derivatives with high affinity for 5-HT1A receptors

Also Published As

Publication number Publication date
FR2753968A1 (fr) 1998-04-03
PL190221B1 (pl) 2005-11-30
WO1998013349A3 (fr) 1998-11-05
CA2267247A1 (fr) 1998-04-02
AU731459B2 (en) 2001-03-29
EP0929525A2 (fr) 1999-07-21
IL128917A (en) 2003-10-31
NO991481D0 (no) 1999-03-26
RU2176639C2 (ru) 2001-12-10
AU4463797A (en) 1998-04-17
IL128917A0 (en) 2000-02-17
NO991481L (no) 1999-03-26
DE69715223T2 (de) 2003-04-30
ATE223380T1 (de) 2002-09-15
EP0929525B1 (fr) 2002-09-04
TW425390B (en) 2001-03-11
FR2753968B1 (fr) 1998-11-27
JP2001503393A (ja) 2001-03-13
DK0929525T3 (da) 2002-12-02
PL332480A1 (en) 1999-09-13
AR008486A1 (es) 2000-01-19
WO1998013349A2 (fr) 1998-04-02
CA2267247C (fr) 2009-05-05
MY118992A (en) 2005-02-28
BR9711560A (pt) 1999-08-24
DE69715223D1 (de) 2002-10-10
HUP0001189A3 (en) 2001-12-28
US6063784A (en) 2000-05-16
NZ334623A (en) 1999-09-29
NO311935B1 (no) 2002-02-18
HUP0001189A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
HN2001000027A (es) Derivados de purina
CL2004001129A1 (es) Compuestos derivados de halogenopirimidinas aril tio-eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
AR028948A1 (es) Compuestos novedosos
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
ECSP077236A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
ES2192301T3 (es) Derivados de resorcinol.
HN2002000300A (es) Nuevos derivados de piperazina
BR0207543A (pt) Quinolinona tricìclica e quinolina tricìclica como compostos moduladores de receptor de androgênio
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
PA8452701A1 (es) Agonistas de prostaglandinas
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
ECSP056256A (es) Moduladores delta-opioides triciclicos
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
BR9909486A (pt) Compostos calcilìticos
SE9901077D0 (sv) Novel use
GT200200235A (es) Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
PA8654701A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion